Internalization of sst2, sst3, and sst5 Receptors: Effects of Somatostatin agonists and antagonists

Journal of Nuclear Medicine

Volumn 47, Issue 3, 2006, Pages 502-511

  Cescato, Renzo ^a   Schulz, Stefan ^b   Waser, Beatrice ^a   Eltschinger, Véronique ^a   Rivier, Jean E ^c   Wester, Hans Jürgen ^d   Culler, Michael ^e   Ginj, Mihaela ^f   Liu, Qisheng ^g   Schonbrunn, Agnes ^g   Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e IPSEN   (France)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Antagonist; Receptor immunocytochemistry; Receptor internalization; Somatostatin receptors; Tumor targeting

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; OCTREOTIDE; PENTETIC ACID; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INTERNALIZATION; MORPHOLOGICAL TRAIT; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; ANIMAL; CELL LINE; CHO CELL; CRICETULUS; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; HAMSTER; KIDNEY; METABOLISM; METHODOLOGY; SCINTISCANNING;

ANIMALS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DELIVERY SYSTEMS; HUMANS; IODINE RADIOISOTOPES; KIDNEY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 33646005541     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
2. Kwekkeboom DJ, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704-1713.
3. Schottelius M, Poethko T, Herz M, et al. Featured article: first (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res. 2004;10:3593-3606.
4. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338-1347.
5. 99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med. 2003;30:247-258.
6. Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res. 2003;63:6864-6869.
7. de Jong M, Bernard BF, De Bruin E, et al. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun. 1998;19:283-288.
8. Schottelius M, Reubi JC, Eltschinger V, Schwaiger M, Wester HJ. N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. J Med Chem. 2005;48:2778-2789.
9. Koenig JA, Edwardson JM. Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci. 1997;18:276-287.
10. Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull. 2001;56:441-451.
11. Roettger BF, Ghanekar D, Rao R, et al. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol. 1997;51:357-362.
12. Bhowmick N, Narayan P, Puett D. The endothelin subtype A receptor undergoes agonist- and antagonist-mediated internalization in the absence of signaling. Endocrinology. 1998;139:3185-3192.
13. Pheng LH, Dumont Y, Fournier A, Chabot JG, Beaudet A, Quirion R. Agonist- and antagonist-induced sequestration/internalization of neuropeptide Y Y1 receptors in HEK293 cells. Br J Pharmacol. 2003;139:695-704.
14. Liu Q, Cescato R, Dewi DA, Rivier J, Reubi JC, Schonbrunn A. Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Mol Pharmacol. 2005;68:90-101.
15. Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W. Regulation and function of somatostatin receptors. J Neurochem. 2004;89:1057-1091.
16. Csaba Z, Dournaud P. Cellular biology of somatostatin receptors. Neuropeptides. 2001;35:1-23.
17. Saveanu A, Gunz G, Dufour H, et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab. 2001;86:140-145.
18. Reubi JC, Eisenwiener KP, Rink H, Waser B, Macke HR. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol. 2002;456:45-49.
19. Reubi JC. Evidence for two somatostatin-14 receptor types in rat brain cortex. Neurosci Lett. 1984;49:259-263.
20. Cai RZ, Szoke B, Lu R, Fu D, Redding TW, Schally AV. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A. 1986;83:1896-1900.
21. Taylor JE, Bogden AE, Moreau JP, Coy DH. In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochem Biophys Res Commun. 1988;153:81-86.
22. Shimon I, Taylor JE, Dong JZ, et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures: differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest. 1997;99:789-798.
23. Hannon JP, Nunn C, Stolz B, et al. Drug design at peptide receptors: somatostatin receptor ligands. J Mol Neurosci. 2002;18:15-27.
24. Rohrer SP, Birzin ET, Mosley RT, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998;282:737-740.
25. Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res. 2005;11:1136-1145.
26. Reubi JC, Schaer JC, Waser B, et al. Affinity profiles for human somatostatin receptor sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282.
27. Schottelius M, Rau F, Reubi JC, Schwaiger M, Wester HJ. Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydration chemistry. Bioconjug Chem. 2005;16:429-437.
28. Rajeswaran WG, Hocart SJ, Murphy WA, Taylor JE, Coy DH. Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist. J Med Chem. 2001;44:1305-1311.
29. Reubi JC, Schaer JC, Wenger S, et al. sst3-selective potent peptidic somatostatin receptor antagonists. Proc Natl Acad Sci U S A. 2000;97:13973-13978.
30. Gu Y-Z, Schonbrunn A. Coupling specificity between somatostatin receptor sst2A and G proteins: isolation of the receptor-G protein complex with a receptor antibody. Mol Endocrinol. 1997;11:527-537.
31. Reubi JC, Kappeler A, Waser B, Laissue JA, Hipkin RW, Schonbrunn A. Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol. 1998;153:233-245.
32. Hipkin RW, Friedman J, Clark RB, Eppler CM, Schonbrunn A. Agonist-induced desensitization, internalization and phosphorylation of the sst2A somatostatin receptor. J Biol Chem. 1997;272:13869-13876.
33. Roth A, Kreienkamp HJ, Meyerhof W, Richter D. Phosphorylation of four amino acid residues in the carboxyl terminus of the rat somatostatin receptor subtype 3 is crucial for its desensitization and internalization. J Biol Chem. 1997;272:23769-23774.
34. Tulipano G, Stumm R, Pfeiffer M, Kreienkamp HJ, Hollt V, Schulz S. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem. 2004;279:21374-21382.
35. Kreuzer OJ, Krisch B, Dery O, Bunnett NW, Meyerhof W. Agonist-mediated endocytosis of rat somatostatin receptor subtype 3 involves beta-arrestin and clathrin coated vesicles. J Neuroendocrinol. 2001;13:279-287.
36. Menard L, Ferguson SS, Zhang J, et al. Synergistic regulation of beta2-adrenergic receptor sequestration: intracellular complement of beta-adrenergic receptor kinase and beta-arrestin determine kinetics of internalization. Mol Pharmacol. 1997;51:800-808.
37. Stroh T, Jackson AC, Sarret P, et al. Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis. Endocrinology. 2000;141:354-365.
38. Erchegyi J, Hoeger CA, Low W, et al. Somatostatin receptor 1 selective analogues: 2. N(alpha)-methylated scan. J Med Chem. 2005;48:507-514.
39. Rivier JE, Kirby DA, Erchegyi J, et al. Somatostatin receptor 1 selective analogues: 3. dicyclic peptides. J Med Chem. 2005;48:515-522.